{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:03:38Z","timestamp":1789646618012,"version":"4.0.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,17]]},"DOI":"10.7759\/cureus.116412","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:16:14Z","timestamp":1789643774000},"source":"Crossref","is-referenced-by-count":0,"title":["De-escalating Therapy in Obstructive Sleep Apnoea After Glucagon-Like Peptide-1 Receptor Agonist-Induced Weight Loss: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Wares","family":"Jalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Obstructive sleep apnea diagnosis and management","volume":"114","author":"Goyal M","year":"2017","unstructured":"Goyal M, Johnson J. Obstructive sleep apnea diagnosis and management. Mo Med. 2017, 114:120-4.","journal-title":"Mo Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-026-02164-6","article-title":"Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications","volume":"18","author":"Soliman AR","year":"2026","unstructured":"Soliman AR, Abouzeid A, Ahmed HH. Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications. Diabetol Metab Syndr. 2026, 18:112. 10.1186\/s13098-026-02164-6","journal-title":"Diabetol Metab Syndr"},{"key":"ref3","unstructured":"National Institute for Health and Care Excellence. Obstructive sleep apnoea\/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s. (2021). Accessed. August 3, 2026: https:\/\/www.nice.org.uk\/guidance\/ng202."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0182-2025","article-title":"The role of weight management in sleep disordered breathing","volume":"21","author":"Griffin W","year":"2025","unstructured":"Griffin W, le Roux CW, Heneghan HM, O'Shea D, Garvey JF. The role of weight management in sleep disordered breathing. Breathe (Sheff). 2025, 21:250182. 10.1183\/20734735.0182-2025","journal-title":"Breathe (Sheff)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1719923","article-title":"Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions","volume":"16","author":"Song GQ","year":"2025","unstructured":"Song GQ, Hu GQ. Comparative impact of different weight loss strategies on obstructive sleep apnea: an integrated review of surgical, pharmacological, and lifestyle interventions. Front Neurol. 2025, 16:1719923. 10.3389\/fneur.2025.1719923","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra A","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024, 391:1193-205. 10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-026-00707-6","article-title":"The role of GLP-1 receptor agonists and multi-agonist incretin therapies for specific obesity-related health conditions: evidence and rationale for prioritisation","volume":"15","author":"Albor C","year":"2026","unstructured":"Albor C, Anyiam O, Boyle LD, et al.. The role of GLP-1 receptor agonists and multi-agonist incretin therapies for specific obesity-related health conditions: evidence and rationale for prioritisation. Curr Obes Rep. 2026, 15:29. 10.1007\/s13679-026-00707-6","journal-title":"Curr Obes Rep"},{"key":"ref8","article-title":"Obstructive Sleep Apnoea\/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome in over 16s Evidence Review M: Demonstration of Efficacy","year":"2021","unstructured":"Obstructive Sleep Apnoea\/Hypopnoea Syndrome and Obesity Hypoventilation Syndrome in over 16s Evidence Review M. Demonstration of Efficacy.     National Institute for Health and Care Excellence, 2021."},{"key":"ref9","unstructured":"National Institute for Health and Care Excellence. Obstructive sleep apnoea syndrome. scenario, management of sleep apnoea. Clinical knowledge summaries. (2026). Accessed: August 3, 2026: https:\/\/cks.nice.org.uk\/topics\/obstructive-sleep-apnoea-syndrome\/management\/management\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2437525","article-title":"Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review","volume":"26","author":"El-Solh AA","year":"2025","unstructured":"El-Solh AA, Gould E, Aibangbee K, Jimerson T, Hartling R. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. Expert Opin Pharmacother. 2025, 26:51-62. 10.1080\/14656566.2024.2437525","journal-title":"Expert Opin Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2024-0193","article-title":"Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review","volume":"36","author":"Alluri AA","year":"2025","unstructured":"Alluri AA, Mohan Kurien M, Pokar NP, Madarapu A, Sadam S, Puvvala N, Seetharaman R. Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review. J Basic Clin Physiol Pharmacol. 2025, 36:13-25. 10.1515\/jbcpp-2024-0193","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/resp.70282","article-title":"GLP-1-based therapy for obstructive sleep apnoea","volume":"31","author":"Zheng Y","year":"2026","unstructured":"Zheng Y, Yee BJ. GLP-1-based therapy for obstructive sleep apnoea. Respirology. 2026, 31:866-8. 10.1002\/resp.70282","journal-title":"Respirology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.10.027","article-title":"GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity","volume":"132","author":"Romariz L","year":"2025","unstructured":"Romariz L, Ara\u00fajo B, Barbosa LM, Jain R, Porto Silva Janovsky CC. GLP-1 receptor agonists for the treatment of obstructive sleep apnea and obesity. Eur J Intern Med. 2025, 132:153-5. 10.1016\/j.ejim.2024.10.027","journal-title":"Eur J Intern Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ohbm5020012","article-title":"The emerging role of pharmacotherapy in obstructive sleep apnea","volume":"5","author":"Jaganathan N","year":"2024","unstructured":"Jaganathan N, Kwon Y, Healy WJ, Taskar V. The emerging role of pharmacotherapy in obstructive sleep apnea. J Otorhinolaryngol Hear Balanc Med. 2024, 5:12. 10.3390\/ohbm5020012","journal-title":"J Otorhinolaryngol Hear Balanc Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2574848","article-title":"The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea","volume":"26","author":"Mifsud CS","year":"2025","unstructured":"Mifsud CS, Kolla BP, Rushlow DR, Mansukhani MP. The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea. Expert Opin Pharmacother. 2025, 26:1529-38. 10.1080\/14656566.2025.2574848","journal-title":"Expert Opin Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12010011","article-title":"The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review","volume":"12","author":"Le KD","year":"2024","unstructured":"Le KD, Le K, Foo F. The impact of glucagon-like peptide 1 receptor agonists on obstructive sleep apnoea: a scoping review. Pharmacy (Basel). 2024, 12:10.3390\/pharmacy12010011","journal-title":"Pharmacy (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae280","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis","volume":"48","author":"Li M","year":"2025","unstructured":"Li M, Lin H, Yang Q, Zhang X, Zhou Q, Shi J, Ge F. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis. Sleep. 2025, 48:10.1093\/sleep\/zsae280","journal-title":"Sleep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2025.02.010","article-title":"Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"129","author":"Kow CS","year":"2025","unstructured":"Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Efficacy and safety of GLP-1 receptor agonists in the management of obstructive sleep apnea in individuals without diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. Sleep Med. 2025, 129:40-4. 10.1016\/j.sleep.2025.02.010","journal-title":"Sleep Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-026-03681-4","article-title":"Efficacy of GLP-1 Receptor agonists in treating obstructive sleep apnea: a systematic review and meta-analysis of cardiometabolic and respiratory outcomes","volume":"30","author":"Dandamudi M","year":"2026","unstructured":"Dandamudi M, Lucena L, Gamarra-Valverde NN, et al.. Efficacy of GLP-1 Receptor agonists in treating obstructive sleep apnea: a systematic review and meta-analysis of cardiometabolic and respiratory outcomes. Sleep Breath. 2026, 30:138. 10.1007\/s11325-026-03681-4","journal-title":"Sleep Breath"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0097-2018","article-title":"Obesity hypoventilation syndrome","volume":"28","author":"Masa JF","year":"2019","unstructured":"Masa JF, P\u00e9pin JL, Borel JC, Mokhlesi B, Murphy PB, S\u00e1nchez-Quiroga M\u00c1. Obesity hypoventilation syndrome. Eur Respir Rev. 2019, 28:10.1183\/16000617.0097-2018","journal-title":"Eur Respir Rev"},{"key":"ref21","unstructured":"British Thoracic Society. Position statement. Driving and obstructive sleep apnoea. (2026). Accessed: August 3, 2026: https:\/\/www.brit-thoracic.org.uk\/about-us\/position-statements\/."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01272-2020","article-title":"European Respiratory Society statement on sleep apnoea, sleepiness and driving risk","volume":"57","author":"Bonsignore MR","year":"2021","unstructured":"Bonsignore MR, Randerath W, Schiza S, et al.. European Respiratory Society statement on sleep apnoea, sleepiness and driving risk. Eur Respir J. 2021, 57:10.1183\/13993003.01272-2020","journal-title":"Eur Respir J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman A","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, et al.. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016, 40:1310-9. 10.1038\/ijo.2016.52","journal-title":"Int J Obes (Lond)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/annalsats\/aaoaf070","article-title":"Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity","volume":"23","author":"Wu JY","year":"2026","unstructured":"Wu JY, Lin YM, Hsu WH, et al.. Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity. Ann Am Thorac Soc. 2026, 23:584-96. 10.1093\/annalsats\/aaoaf070","journal-title":"Ann Am Thorac Soc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038856","article-title":"Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)","volume":"10","author":"Sprung VS","year":"2020","unstructured":"Sprung VS, Kemp GJ, Wilding JP, et al.. Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ Open. 2020, 10:e038856. 10.1136\/bmjopen-2020-038856","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045445","article-title":"Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: a case report","volume":"104","author":"Funamizu N","year":"2025","unstructured":"Funamizu N, Funamizu N, Hirose T. Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: a case report. Medicine (Baltimore). 2025, 104:e45445. 10.1097\/MD.0000000000045445","journal-title":"Medicine (Baltimore)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2025.106719","article-title":"Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity","volume":"134","author":"Kanu C","year":"2025","unstructured":"Kanu C, Shinde S, Chakladar S, Dennehy EB, Weaver TE, Poon JL, Malhotra A. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025, 134:106719. 10.1016\/j.sleep.2025.106719","journal-title":"Sleep Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-026-00808-3","article-title":"Patients\u2019 experiences of obstructive sleep apnea and tirzepatide treatment: an exit interview study","volume":"19","author":"Shinde S","year":"2026","unstructured":"Shinde S, Kanu C, Varnado OJ, Bednarik J, Dennehy EB, Dias-Barbosa C, Taylor N. Patients\u2019 experiences of obstructive sleep apnea and tirzepatide treatment: an exit interview study. Patient. 2026, 19:601-14. 10.1007\/s40271-026-00808-3","journal-title":"Patient"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-026-03748-2","article-title":"GLP-1 receptor agonists and risk of cardiovascular and pulmonary complications in patients with OSA and type 2 diabetes mellitus","volume":"30","author":"Borissov Borissov M","year":"2026","unstructured":"Borissov Borissov M, Hwang SY, Wickwire EM, So JY. GLP-1 receptor agonists and risk of cardiovascular and pulmonary complications in patients with OSA and type 2 diabetes mellitus. Sleep Breath. 2026, 30:199. 10.1007\/s11325-026-03748-2","journal-title":"Sleep Breath"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2024.06.014","article-title":"Weight reduction and the impact on apnea-hypopnea index: a systematic meta-analysis","volume":"121","author":"Malhotra A","year":"2024","unstructured":"Malhotra A, Heilmann CR, Banerjee KK, Dunn JP, Bunck MC, Bednarik J. Weight reduction and the impact on apnea-hypopnea index: a systematic meta-analysis. Sleep Med. 2024, 121:26-31. 10.1016\/j.sleep.2024.06.014","journal-title":"Sleep Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200707-114MG","article-title":"Pathophysiology of adult obstructive sleep apnea","volume":"5","author":"Eckert DJ","year":"2008","unstructured":"Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008, 5:144-53. 10.1513\/pats.200707-114MG","journal-title":"Proc Am Thorac Soc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy624","article-title":"The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study","volume":"40","author":"Azarbarzin A","year":"2019","unstructured":"Azarbarzin A, Sands SA, Stone KL, et al.. The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Eur Heart J. 2019, 40:1149-57. 10.1093\/eurheartj\/ehy624","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202309-821OC","article-title":"Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study","volume":"21","author":"O'Donnell C","year":"2024","unstructured":"O'Donnell C, Crilly S, O'Mahony A, et al.. Continuous positive airway pressure but not GLP1-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: a randomized proof-of-concept study. Ann Am Thorac Soc. 2024, 21:464-73. 10.1513\/AnnalsATS.202309-821OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-025-03309-z","article-title":"Impact of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial","volume":"29","author":"Wali SO","year":"2025","unstructured":"Wali SO, Batawi G, Kanbr O, et al.. Impact of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Sleep Breath. 2025, 29:146. 10.1007\/s11325-025-03309-z","journal-title":"Sleep Breath"},{"key":"ref35","article-title":"Home sleep apnea testing for obstructive sleep apnea","volume":"121","author":"Hussein O","year":"2024","unstructured":"Hussein O, Alkhader A, Gohar A, Bhat A. Home sleep apnea testing for obstructive sleep apnea. Mo Med. 2024, 121:60-5.","journal-title":"Mo Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.12.142","article-title":"Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model","volume":"10","author":"Schwarz EI","year":"2018","unstructured":"Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis. 2018, 10:S24-32. 10.21037\/jtd.2017.12.142","journal-title":"J Thorac Dis"},{"key":"ref38","unstructured":"Driver and Vehicle Licensing Agency. Excessive sleepiness and driving. (2026). Accessed. August 3, 2026: https:\/\/www.gov.uk\/excessive-sleepiness-and-driving."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2025.277","article-title":"Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia","volume":"41","author":"Kang D","year":"2026","unstructured":"Kang D, Choi D. Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia. Korean J Intern Med. 2026, 41:384-95. 10.3904\/kjim.2025.277","journal-title":"Korean J Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2024.01.001","article-title":"Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration","volume":"132","author":"van Zuylen ML","year":"2024","unstructured":"van Zuylen ML, Siegelaar SE, Plummer MP, Deane AM, Hermanides J, Hulst AH. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024, 132:644-8. 10.1016\/j.bja.2024.01.001","journal-title":"Br J Anaesth"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526950-de-escalating-therapy-in-obstructive-sleep-apnoea-after-glucagon-like-peptide-1-receptor-agonist-induced-weight-loss-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:16:18Z","timestamp":1789643778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526950-de-escalating-therapy-in-obstructive-sleep-apnoea-after-glucagon-like-peptide-1-receptor-agonist-induced-weight-loss-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.116412","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}